The Canadian veterinary journal = La revue veterinaire canadienne · 2026
Comparison of pre-weaning bovine respiratory disease treatment rates between non-vaccinated control and variably primed and boosted beef calves receiving commercially available bovine coronavirus vaccines.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Erickson Nathan E N, Ware Tommy, Campbell John, Larson Kathy, Ellis John A, Waldner Cheryl L
Аннотация
OBJECTIVE: The primary objective was to determine effectiveness of bovine coronavirus (BCoV) vaccination of neonatal calves in the face of natural respiratory infection in a commercial herd.
ANIMALS: At a privately owned ranch in north-central Alberta with a history of bovine respiratory disease (BRD), beef calves of mixed sex and breed were randomized into a clinical vaccine trial.
PROCEDURE: At birth, 447 calves were enrolled into the vaccine (VAC) group and administered an intranasal dose of BCoV vaccine, and 439 calves were enrolled as controls (CON). Most VAC calves (n = 389) also received an intramuscular dose of BCoV vaccine at an average of 49 d (SD: 7 d). Treatment for BRD and total mortality were recorded until pasture turnout. Weaning weights were collected at the end of the grazing season. A partial budget comparison included costs of vaccination and treatment, as well as potential revenues using weaning weights and regional sale summaries.
RESULTS: Calves in the CON group were more likely than VAC calves to be treated before turnout vaccination (OR: 1.50; P = 0.048) and calves born in the 2nd cycle were more likely than 3rd-cycle calves to be treated for BRD (OR: 2.90; P = 0.01). The odds of mortality for CON calves born in the 2nd cycle were higher (OR: 4.8; P = 0.001) than for VAC calves. Weaning weights were higher for VAC calves (P = 0.04) and, despite increased costs due to vaccination, revenue for VAC calves was an average of $10.50/head higher.
CONCLUSION: Vaccination of neonatal calves with BCoV vaccine reduced the frequency of BRD treatment and total mortality and improved weaning weights and revenue potential in this herd.
CLINICAL RELEVANCE: Vaccination with commercial BCoV vaccines could be an important tool to control neonatal BRD, particularly in herds with a history of disease not responsive to other BRD vaccines.
ANIMALS: At a privately owned ranch in north-central Alberta with a history of bovine respiratory disease (BRD), beef calves of mixed sex and breed were randomized into a clinical vaccine trial.
PROCEDURE: At birth, 447 calves were enrolled into the vaccine (VAC) group and administered an intranasal dose of BCoV vaccine, and 439 calves were enrolled as controls (CON). Most VAC calves (n = 389) also received an intramuscular dose of BCoV vaccine at an average of 49 d (SD: 7 d). Treatment for BRD and total mortality were recorded until pasture turnout. Weaning weights were collected at the end of the grazing season. A partial budget comparison included costs of vaccination and treatment, as well as potential revenues using weaning weights and regional sale summaries.
RESULTS: Calves in the CON group were more likely than VAC calves to be treated before turnout vaccination (OR: 1.50; P = 0.048) and calves born in the 2nd cycle were more likely than 3rd-cycle calves to be treated for BRD (OR: 2.90; P = 0.01). The odds of mortality for CON calves born in the 2nd cycle were higher (OR: 4.8; P = 0.001) than for VAC calves. Weaning weights were higher for VAC calves (P = 0.04) and, despite increased costs due to vaccination, revenue for VAC calves was an average of $10.50/head higher.
CONCLUSION: Vaccination of neonatal calves with BCoV vaccine reduced the frequency of BRD treatment and total mortality and improved weaning weights and revenue potential in this herd.
CLINICAL RELEVANCE: Vaccination with commercial BCoV vaccines could be an important tool to control neonatal BRD, particularly in herds with a history of disease not responsive to other BRD vaccines.